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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
narrowband UVB (NB-UVB) phototherapy in combination with nonsteroidal topical medications 
is more effective at repigmentation of vitiligo lesions when compared to NB-UVB therapy alone 
in healthy men and women between the ages of 11 and 69. 
 
STUDY DESIGN: Review of three peer-reviewed randomized controlled trials written in 
English, two of which were published in 2014, and one in 2011. 
 
DATA SOURCES: Studies were selected based on the method of study, the randomized- control 
structure of the studies, and the relevance to the clinical question, and all were identified as 
patient-oriented evidence that matters (POEMS).  
 
OUTCOMES MEASURED: A variety of methods were used to evaluate the outcomes of 
treatment, including visual analog scale (VAS), Patient Global Assessment (PGA),  Investigator 
Global Assessment (IGA), VisitrakTM, palm thumb method, vitiligo scoring index (VASI), and 
the Lund and Browder (L & B) index. 
 
RESULTS: Three different nonsteroidal topicals were used in conjunction with NB-UVB, 
calcipotriol, tetracycline, and 0.1% tacrolimus ointment. Of these three topicals, only 0.1% 
tacrolimus ointment in combination with NB-UVB was shown to have a significant result, with a 
13.1% reduction in lesions and a P value of 0.005, indicating a difference when compared to 
NB-UVB therapy alone. The P values for the other two studies were very similar, with values of 
0.557, and 0.566, suggesting they have no enhancing effect when used with NB-UVB. 
 
CONCLUSION: Two of the three studies analyzed concluded that the addition of a nonsteroidal 
ointment to NB-UVB was not more effective than NB-UVB alone. The only topical that had 
statistical support was 0.1% tacrolimus ointment, an immunosuppressive agent, suggesting that 
this topical enhances treatment outcome when used with NB-UVB. NB-UVB is a gold standard 
of care for the treatment of generalized vitiligo. Immunosuppressive agents, such as tacrolimus, 
when added benefit patients by decreasing a larger area of depigmentation. Further research is 
warranted to obtain a better understanding of the role of nonsteroidal immunosuppressive 
ointments in vitiligo treatment.  
 
KEY WORDS: vitiligo, NB-UVB, topical tetracycline, tacrolimus 
 
 
 
 
 
 
 
 
 
	  Baier, Nonsteroidal Topical and NB-UVB Treatment of Vitiligo 1 
 
INTRODUCTION 
  
 Vitiligo is an acquired skin disorder that results in macules and patches of 
depigmentation most commonly found on sun-exposed areas of skin. Vitiligo is autoimmune in 
nature, as the melanocytes, the cells that produce the skin’s pigment, are destroyed. Vitiligo 
affects 1% of the world’s population, with generalized vitiligo (vitiligo vulgaris) being the most 
common; it is symmetric in distribution and widespread throughout the body. Other types of 
vitiligo include acrofacial (extensor surfaces and orifices), segmental, focal, mucosal, and 
universal. Vitiligo affects all age groups and races but most often erupts in childhood and early 
adulthood. Vitiligo is asymptomatic, but its unsightly appearance draws patients to seek medical 
advice and treatment. Interestingly, vitiligo is associated with many other autoimmune disorders, 
including hypothyroidism, alopecia areata, and Addison’s disease.  Its degree of heritability is 
approximately 30%. Some have hypothesized that it is brought on by stress, trauma, or even 
sunburn, but none of these causes have been confirmed. Vitiligo is typically a clinical diagnosis, 
but a skin biopsy can be completed for a definitive diagnosis.  Although vitiligo currently has no 
cure, several treatment options are available. 
 Annually, an average of 1.8 million people visit physician offices with concerns 
pertaining to vitiligo, 39,000 seek treatment from hospital outpatient departments, and 137 
million dollars are spent on patients with vitiligo. 1 Vitiligo causes psychological anguish in 
patients, as they are singled out for looking different. Skin condition is crucial for both mental 
and physiological well-being because it influences relationships, occupation, and self-esteem. In 
some cultures, patients with vitiligo are completely ostracized. For example, Indian culture 
regards vitiligo as Sweta Kustha, meaning, “white leprosy.” 2 Thus, continued research on more 
effective treatment options is invaluable to these patients. 
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 Some popular treatment modalities used include ultraviolet light (sometimes used in 
combination with other therapies), corticosteroids, calcineurin inhibitors, excimer lasers/lamps, 
and cosmetic interventions. Ultraviolet radiation, particularly NB-UVB, has shown great promise 
for those who have extensive generalized vitiligo, and numerous studies have shown that it is 
more effective and has less of a side effect profile when compared to ultraviolet A therapy 
(PUVA). This type of treatment is time consuming, however, requiring patients to visit their 
physician’s office an average of 3 times a week for 6 to12 months. Corticosteroids, on the other 
hand, are usually considered first line when lesions are limited (< 10% body surface area [BSA]); 
however, this has to be monitored closely because of  the risk of skin atrophy. Calcineurin 
inhibitors, such as tacrolimus and pimecrolimus, are topicals that do not cause skin atrophy and 
are particularly useful when treating vitiligo on the face. Research has begun to look at their 
efficacy when used in combination with UVB light and laser treatments, and results are 
promising. Evidence regarding other nonsteroidal ointments, such as topical vitamin D analogs 
(calcipotriol), is less convincing  partly as a result of lack of research. Few studies have looked at 
its potential when used in combination with NB-UVB therapy. Another modality, the excimer 
lamp/laser, is used for small areas of vitiligo but has not shown superiority to UBV light. Finally, 
cosmetic camouflage using dye/pigment preparations can be used for those who do not want 
medical intervention. All of these interventions have been proved in at least one setting to 
decrease the area of depigmentation in patients with vitiligo. Steroids are typically first line, but 
because of the high incidence of skin atrophy, an alternative nonsteroidal is being investigated. 
NB-UVB is considered a standard of care, but because it is time consuming, a combined therapy 
with nonsteroidal ointment may be able to cut down on light therapy sessions. 
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OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not NB-UVB 
phototherapy in combination with nonsteroidal topical medications is more effective at 
repigmentation of vitiligo when compared to NB-UVB therapy alone in healthy men and women 
between the ages of 11 and 69 years. 
METHODS 
 The criteria for selection included that the population consist of healthy male participants 
and healthy female participants who were not pregnant. Participants also had to be older than age 
11 years and younger than age 69 years and classified as having stable generalized vitiligo. 
Patients also must not have had recent prior treatment. Only randomized controlled right/left 
comparative trials that compared NB-UVB therapy in combination with a nonsteroidal 
medicated ointment on one side of the patient’s body compared to controlled groups of NB-UVB 
therapy alone or in combination with a placebo ointment on the opposite side of that same 
patient’s body. The nonsteroidal adjunctive therapy included tacrolimus 0.1% ointment, 
calcipotriol ointment, and tetracycline ointment. The outcome was based on the repigmentation 
of vitiligo lesions. The studies by Nordal and Kalafi, utilized tacrolimus and tetracycline, 
respectively, were randomized, controlled, and double blind. 3,4 The study by Khuller, which 
analyzed calcipotriol, was a right/ left prospective comparative trial that did not use a placebo 
ointment and was not double blind.5 
 In order to find ideal articles, the keywords used included vitiligo, NB-UVB, topical 
tetracycline, and tacrolimus. These keywords were researched by the author using PubMed in 
December 2014. All articles were randomized controlled trials, published in English and peer-
reviewed, and were selected based on the clinical relevance concerning NB-UVB therapy in 
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combination with a nonsteroidal with an appropriate control side of NB-UVB alone or with 
placebo ointment. Articles especially needed to address the patients’ concerns with the size of 
depigmented lesions in generalized vitiligo. Each study was highly selective regarding inclusion 
and exclusion criteria listed in Table 1. Articles were excluded if published before the year 2000, 
if participants were younger than 11 or older than 69 years old, if PUVA was used, or if studies 
contained a steroidal topical. Statistical values of interest included P values, mean change from 
baseline, confidence intervals, absolute benefit increase (ABI), relative benefit increase (RBI), 
and number needed to treat (NNT). 
Table 1: Demographics and characteristics of included studies 
Study Type # 
pts 
Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W/
D 
Interventions 
Kalafi, 
2014 3 
Randomized 
controlled 
double-blind 
placebo study 
30 11-66 Generalized, stable 
vitiligo 
(nonprogressive or 
no new lesions in 
the previous 3 
months)   
 
Pregnant or lactating 
patients,  
children < 8 years old,   
photodermatoses or 
cutaneous malignancy, 
used other medications 
for vitiligo in the 
previous 3 months 
0 Topical 
tetracycline 
on one side 
vs. Vaseline 
placebo on 
the other side 
twice per day,  
NB-UVB 
therapy 2-3 
times per 
week for 12 
weeks.  
 
Khullar, 
20144 
Randomized 
right-left 
prospective 
comparative 
clinical trial 
27 12-60 Male or female aged 
12-60 years,  
5-50% of body 
surface area, 
stable or slowly 
progressive disease, 
B/L symmetrical 
patches;  
no topical treatment 
in last 2 weeks or 
systemic treatment 
in previous 4 weeks 
 
Pts with segmental, 
universal, palmo-
plantar, or  
mucosal vitiligo,  
photosensitivity 
dermatoses,  
immunosuppression,   
impaired liver or renal 
function,  
hypercalcemia or 
hypercalciuria   
Urolithiasis, 
concomitant use of 
medications affecting 
calcium metabolism,  
pregnant or lactating 
women  
 
2 Half of body 
topical 
calcipotriol 
applied 
twice/day + 
NB-UVB 
therapy 
(TIW) vs. 
UVB therapy 
alone on 
opposite site 
for 24 weeks 
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Nordal, 
20115 
Randomized 
controlled trial 
46 23-69  > 18 yrs old 
Fitzpatrick skin type 
II-VI  
Symmetric  
Pregnant and breast 
feeding 
6 Tacrolimus 
0.1% 
ointment on 
one side of 
body and 
Protopic base 
placebo 
ointment on 
opposite side 
every 
night+NB-
UVB 3times/ 
week for 3 
mos with 3 
mo f/u 
 
OUTCOMES MEASURED 
 All three studies used slightly different measurements, but all revolved around patient-
centered concerns regarding the area of depigmentation. The Kalafi study used the VASI score, a 
clinician-used index that measures percent depigmentation, where scores were broken down as 
follows: 100% = total depigmentation, 90% = speck of pigmentation, 75% = more depigmented 
areas than pigmented areas, 50% = equal pigmented and depigmented areas, 25% = more 
pigmented areas than depigmented areas, and 10% = specks of depigmentation.4 The Khuller 
study used a combination of L&B index score, a chart that measures BSA affected; IGA, a 
subjective reading by the investigator that uses a scale from -1-5 with -1 indicating worsening 
and 5 indicating 100% repigmentation; and PGA, a subjective reading from the patient ranging 
from 1-10, with 10 indicating maximum disease at baseline. The Nordal study employed the 
VAS, a subjective measure by patients on the impact of living with vitiligo. VisitrakTM was used 
to obtain an objective measure of vitiligo target lesions. Data from VisitrakTM was converted to 
dichotomous data and regarded patients with 20% reduction in depigmentation compared to 
placebo as “high responders,” those with less percentage depigmentation considered “low 
responders,” and those with the same results on both sides considered “non-responders.” 
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RESULTS 
Study 1. In a study by Kalafi, 30 patients at an outpatient dermatology office with generalized 
and stable vitiligo were selected to participate. Patients were instructed to use tetracycline 
ointment twice a day on one side and a Vaseline-based placebo on the opposite side in the same 
amount and position. All participants received NB-UVB 2 to 3 times per week, and data for 
analysis were collected during the 12th week using VASI.  The study gave all values of pre- and 
post-VASI scores for both groups. Thus, to convert these points into dichotomous data, a patient 
was considered to have benefitted significantly from treatment if there was a 25% decrease in the 
area of depigmentation. This method showed that only 1 patient from the treatment side and 1 
patient from the placebo side showed significant improvement. There was a significant change 
from baseline on both sides, with both sides reporting a P value of 0.026; however, when the 
treatment and control side were compared against one another, the P value was recorded as 0.566 
(Table 2). The article referred to successful cases as patients who demonstrated any improvement 
from baseline, stating that 16.6% of patients who used tetracycline showed improvement. 
Likewise, 16.6% of patients who used NB-UVB alone showed a degree of improvement. The 
only adverse effect recorded was stinging at the site of application, but data were not provided, 
so number needed to harm (NNH) was not calculated. The NNT calculation resulted in an error 
message because both treatment modalities had exactly the same effect. 
Table 2: Kalafi study: Topical tetracycline + NB-UVB (experiment) vs. NB-UVB alone 
(control) 
CER (control event 
rate) 
EER 
(experiment 
event rate) 
Relative Benefit 
Increase (RBI) 
Absolute 
Benefit increase 
(ABI) 
Numbers 
Needed to Treat 
(NNT) 
P value  
3% 3% 0 0 N/A- no 
difference 
between tx 
0.566 
*P value was only considered significant if < 0.05. 
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Study 2. Khuller instituted a right/left prospective comparative trial that consisted of 25 patients, 
including both male and female participants aged 12 to60 years with 5 to50% of BSA affected, 
stable, bilateral symmetrical patches, and no use of topical treatment for previous 2 weeks or 
systemic therapy for 4 weeks. The study was randomized as to which side received treatment, 
but was not double blind. Calcipotriol ointment was applied twice per day at night and 2 hours 
after UVB therapy, which was completed 3 times per week. This study used various modalities, 
including L&B index score, IGA, and PGA, to look at change in pigmentation that was of 
particular interest. PGA data were collected but not published; therefore, the IGA scores were 
transformed into dichotomous data, where patient outcome was considered significant if a 50% 
or greater increase in repigmentation occurred (Table 3). Forty-four percent of patients saw 50% 
or greater increase in repigmentation on the treatment side; likewise, 44% of patients also 
demonstrated 50% or more increase in repigmentation on the placebo side. The L&B index 
score, IGA P values, and PGA P values were 0.577, 0.821, and 0.706, respectively, and not 
significant. The mean change from baseline for the NB-UVB side alone collected from the three 
measurement modalities were 51.4 +/- 28.1 (95% CI 39.8-63), 2.7 +/- 0.5 (95% CI 2.0-3.4), and 
5.6 +/- 3.4 (95% CI 4.3-7.0), respectively. The mean changes on the on the calcipotriol side 
included 49.0 +/- 24.5 (95% CI 38.9-59.1), 2.5 +/- 0.4 (95% CI 2.0-3.3), and 5.8 +/- 3.2 (95% CI 
4.4-7.1). Furthermore, repigmentation did not occur earlier in one group than the other, and 
pigment matching to the individual’s skin color was the same in both groups. Repigmentation 
onset was between 3 to10 weeks on both sides, and the difference in onset was not statistically 
significant, P value = 0.533. Collectively, the data are consistent in that treatment in both groups 
was statistically similar. Calcipotriol induced numerous adverse reactions, including erythema, 
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xerosios, pruritis, and folliculitis. Nevertheless, an adverse profile of NB-UVB alone was not 
presented; thus, NNH was not calculated.  
Table 3. Khuller study: Calipotriol + NB-UVB (experiment) vs. NB-UVB alone (control) 
CER 
(control 
event 
rate) 
EER 
(experiment 
event rate) 
Relative 
Benefit 
Increase 
(RBI) 
Absolute 
Benefit 
Increase 
(ABI) 
Number 
Needed to 
Treat 
(NNT) 
P-
Value 
for 
IGA 
scores 
P-
Value 
for 
PGA 
scores 
P-Value 
for L&B 
Repigmentati
on onset  
measured in 
weeks 
44% 44% 0 0 N/A- no 
difference 
in 
treatment 
0.821 0.706 0.557 0.533 
*P value considered significant if < 0.05 
 
Study 3. The study conducted by Nordal researched the usefulness of adding a 0.1% tacrolimus 
ointment to NB-UVB therapy using a randomized right/left, double-blind, comparative study.  
Forty patients were recruited from a dermatology practice at a university hospital. Pregnant and 
breast-feeding patients were excluded likely because tacrolimus is a category C drug. Ointments 
were distributed symmetrically every night for 3 months, and NB-UVB therapy was completed 2 
to3 times per week with a 3-month follow-up. The data that were presented in the study focused 
on target lesion measurements using VisitrackTM; those with 20% improvement compared to 
placebo side were considered high responders (9 participants), those with less improvement were 
considered low responders (19 participants), and the rest were considered nonresponders. 
Overall, there was a median 42.1% decrease in target lesions on the tacrolimus side as compared 
to a median of 29% decrease on the placebo side, with a statistical P value of 0.005 (Table 4). 
Please note that the data presented within the study could not be converted into a dichotomous 
form; thus, ABI, RBI, and NNT could not be calculated. The study also mentions a direct 
correlation between an increase in the reduction in target lesion and an increase in the number of 
tacrolimus applications; however, this correlation was not seen with an increase in NB-UVB 
	  Baier, Nonsteroidal Topical and NB-UVB Treatment of Vitiligo 9 
 
treatments. Although subjective scores using VAS were not published, researchers noted that 
patients with even minimal improvement responded positively while receiving treatment. 
Perioral dermatitis on the tacrolimus side was observed, but no data were published in the study; 
therefore, NNH could not be calculated. 
Table 4: Nordal study: Percent reduction in target lesions of vitiligo Tacrolimus 0.1% 
+NB-UVB 0.1% VS. placebo + NB-UVB 
Median % reduction 
of NB UVB + 
Tacrolimus 
Median % reduction 
of NB-UVB + 
Placebo 
Difference  P value 
42.1 29.0 13.1 0.005 
*P value considered significant if < 0.05 
 
DISCUSSION 
 The goal of this systematic review was to determine if nonsteroidal ointments in 
combination with NB-UVB therapy is more beneficial in the treatment of vitiligo than treatment 
with NB-UVB alone. Vitiligo is a highly treatment-resistant condition, and often one modality 
does not suffice. NB-UVB has much support in the literature, thus reinforcing its efficacy in 
treating generalized vitiligo; however, adjunctive therapies other than topical steroids are less 
recognized. Steroid creams have long been a go-to option for clinicians and patients, but they 
have a significant side effect profile;  therefore, looking into other medicated ointments would be 
worthwhile.  
Of the 3 nonsteroidal ointments studied, only tacrolimus (0.1%) ointment appears to have 
an enhancing effect when used with NB-UVB. Tacrolimus is a calcineurin inhibitor, an 
immunosuppressant, and blocks the release of inflammatory cytokines. Tacrolimus is commonly 
prescribed to treat atopic dermatitis, although it recently has gained attention for its potential to 
treat psoriasis, pyoderma gangrenosum, lichen planus, and vitiligo. A black-box warning on the 
product reports weak linkage between tacrolimus use and malignancy (skin and lymphoma); 
thus, the manufacturers recommend short-term and minimal use. This contradicts the previous 
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misconception that a nonsteroidal would be a better option for long-term topical application, 
especially when tacrolimus quantity and length of use seem to have a direct benefit on vitiligo. 
Nonetheless, more research needs to be completed to obtain a better understanding of the 
association. Topical tetracycline (indicated for impetigo and perioral dermatitis) and calcipotriol 
(indicated for plaque psoriasis) have safer profiles, but after analyzing both studies, they appear 
to have no benefit when used as an adjunctive therapy.  
Larger studies need to be performed; the studies included in this review were limited with 
40, 30, and 25 participants. Also, the quality of the Khullar study was undesirable because it was 
not double blind and did not utilize a placebo ointment. The study was also male dominant with a 
4:1 ratio, did not include an age range of participants, and included 3 acrofacial types of vitiligo, 
while this review focused on the generalized vitiligo type. The study also focused on darker skin 
types III-V.  The Kalafi study exclusively looked at Fitzpatrick skin type III and included 
adolescents and children in the study aged 11-17 years. The Nordal study looked exclusively at 
adults, predominantly women, and the majority of patients studied were Fitzpatrick skin type III 
(22 participants), IV (11 participants), V (1 participant), and VI (1 participant). The sites of 
application varied widely among the three studies, including the knees, arms, face, neck, and 
trunk; each study looked at a combination of these sites. This may be significant because sources 
have identified that tacrolimus may be most beneficial for the head and neck.6 Ideally, studies 
would consist of equal gender, consist of adults or children exclusively, consist of an array of 
skin types with race included, and focus on a certain anatomical site. As a result of the many 
discrepancies across these topics, these results cannot be generalized to everyone, only to those 
mentioned in the respective studies.  
CONCLUSION 
	  Baier, Nonsteroidal Topical and NB-UVB Treatment of Vitiligo 11 
 
 After review of the 3 studies, the benefit of nonsteroidals as an adjunctive therapy is 
inconclusive. All three nonsteroidal were chosen because they have a mechanism that has 
potential to induce repigmentation. Calcipotriol activates a pathway to stimulate melanocyte 
production; whereas tetracycline and tacrolimus reduce inflammatory cytokines. Tacrolimus was 
the only successful therapy in enhancing the effects of NB-UVB. This systemic review was 
intended to be broad to work as a starting point for future research. Since tacrolimus had the 
most promise, a look at different calcineurin inhibitors would be interesting to see if one has 
more of an enhancing effect with NB-UVB than the others, thus potentially lessening 
phototherapy sessions and long-term corticosteroid use. Before additional research in this area 
can begin, however, more research concerning the association between tacrolimus and 
malignancy,  specifically analyzing quantities and time frames in which risk is likely to occur 
must be completed.  Future studies can improve the knowledge base on this topic by focusing on 
a wide range of skin pigment types, specifying a pediatric or adult study, and focusing on 
specific anatomical sites.  
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